Fundraising FoxSectoral Asset Management — Full Portfolio
12 tracked investments · listed companies and verified rows first
Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients.
BiotechDigital HealthHealthtechCambridge, US
Lawrence G. Miller(Executive Officer, Director)inDennis Molnar(Executive Officer)inBarry Wohl(Chief Business Officer)inKetan Mehta(Head of Product and Engineering, Connected Wearables)Ron Farquhar(Director)Gerald Chan(Director)
Co-investorsAlpha Wave GlobalHEALTHCARE ROYALTY PARTNERSMorningside Group
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA CapitalWellington ManagementAlexandriaCity Hill Ventures+4 more
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in
Co-investorsHadean VenturesRed Tree VentureSamsara BioCapitalCasdin CapitalFranklin TempletonJJDC+1 more
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersLSP (Life Sciences Partners)+5 more
BiotechSan Leandro, US
Steve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)inStephen W. Lau(President, Chief Executive Officer, and Treasurer)inKenneth Schwartz(Executive Officer)inEric Yuen(Executive Officer)inMarten Steen(Director)in
Co-investorsHealthCapInkefSofinnova VenturesYsios Capital
CurvaFix develops the CurvaFix Low Profile intramedullary nailing system, curved implants for surgical stabilization of pelvic fractures.
HardwareHealthtechMedical DevicesBellevue, US
Jeffrey Poole(Executive Officer)Mark Foster(Executive Officer, Director)inSteven Dimmer(Executive Officer, Director, Promoter)Dong-Gun Kim(Director)
BoardEric Fritz(Director)inJack Tanaka(Director)in
Co-investorsAlliance of AngelsArieal Southeast Angel PartnersRockies Venture ClubSPRINGROCK VENTURESSwan Venture FundKeiretsu Capital+2 more
LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.
BiotechHealthtechMedical DevicesSan Diego, US
James McCollum(Co-founder, Board Member)Eef SchimmelpenninkinEvert Schimmelpennink(President and CEO)
Co-investorsAlpha Wave GlobalRA CapitalRaptor GroupRTW Investments L.P.Versant Ventures
Magnolia Medical develops diagnostic devices to reduce blood culture contamination and false-positive sepsis test results for hospitals and healthcare systems.
HardwareHealthtechMedical DevicesSeattle, US
Gregory J Bullington(Executive Officer, Director)Richard Patton(Co-founder)
BoardPaul Meister(Director)
Co-investorsEvidity Health CapitalLauder PartnersMarram VenturesRhapsody Venture PartnersVivo CapitalHealthQuest Capital+3 more
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in
BoardJoyce Erony(Director)inWilliam Harrington(Director)in
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+6 more
Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.
Digital HealthMedical DevicesWellness & FitnessPleasanton, US
Shri Raghunathan(Founder)inShriram Raghunathan(Executive Officer, Director)
BoardChau Khuong(Director)inAllan May(Director)Mudit Jain(Director)inTracy Pappas(Director)in
Co-investorsAngelini VenturesBlue Venture FundsJoyance PartnersOrbiMedTreo Ventures, LlcZühlke Ventures+2 more
Phagenesis develops targeted pharyngeal electrical stimulation technology to treat neurogenic dysphagia by restoring neural pathways for safe swallowing.
Deep TechDigital HealthHealthtechMedical Devices
Co-investorsAphelion CapitalInnvotec Ltd.Northern GritstoneEQT Life Sciences
Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.
BiotechHardwareHealthtechMedical DevicesSan Mateo, US
Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)inDr. Joey English(Chief Medical Officer)Tony Chou(Founder)in
BoardJack Lasersohn(Director)inTamir Meiri(Director)
Co-investorsNovo HoldingsThe Vertical GroupNorwest Venture PartnersRunway Growth CapitalUS Venture PartnersSofinnova Ventures+1 more
Shockwave Medical develops intravascular lithotripsy (IVL) catheter systems used to treat calcified cardiovascular disease, marketed to interventional cardiologists and vascular specialists.
HardwareHealthtechMedical DevicesFremont, US
Daniel Hawkins(Executive Officer, Director)inTodd J. Brinton(Director)inIsaac(President)
BoardJay Watkins(Director)inAntoine Papiernik(Director)inFrederic H. Moll(Director)
Co-investorsSofinnova PartnersSonder CapitalVenrock
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.